Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients.
Hermann ToplakAikaterini BilitouHannes AlberJohann AuerMartin ClodiChristoph EbenbichlerEvelyn Fließer-GörzerCarmen GelsingerUrsula HanuschBernhard LudvikThomas MacaAndreas SchoberReinhard SockWalter S SpeidlThomas M StulnigRaimund WeitgasserAndreas ZirlikMarina KochSebastian WienerroitherSorrel E WolowaczFrançoise DiamandAlberico L CatapanoPublished in: Wiener klinische Wochenschrift (2023)
The SANTORINI real-world data in Austria suggest that a proportion of high and very high-risk patients remain below the guideline-recommended low-density lipoprotein cholesterol goals. Optimising use of oral ezetimibe and bempedoic acid after statins in the lipid-lowering pathway could result in substantially more patients attaining low-density lipoprotein cholesterol goals, likely with additional health benefits.